The Biologics Platform Decision
growth strategy
What this case is about
Our client, Orvessa Pharma, is a French pharmaceutical company with a successful history in small-molecule drugs. It wants to enter the fast-growing biologics segment and is considering acquiring Talverin Bio, a San Francisco-area biologics startup. The client wants to know whether to proceed and, if it does, how to assess the pipeline and integrate the research organization.
Objective
Recommend whether Orvessa should pursue the acquisition and establish the diligence, deal conditions, and research-location model needed to capture strategic value while managing pipeline and talent risks.
Skills this case tests
Structuring the problem
Judgement and recommendation
Working the numbers
Communicating clearly
This is an interview practice scenario. Figures in the brief are case inputs, not current market research.